VK2735: A Dual GLP-1/GIP Receptor Agonist in Clinical Development for Obesity

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to VK2735. VK2735 is an investigational compound that is not FDA-approved for any indication. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

A compound can show 14.7% mean weight reduction at 13 weeks and still be two to three years away from FDA approval. VK2735 is in that position. The Phase 2 data are now published. The Phase 3 VANQUISH program has completed enrollment. The regulatory pathway ahead is well-defined but long. For anyone tracking the next wave of obesity pharmacology, VK2735 represents something worth understanding clearly: what its mechanism is, what the evidence actually shows, and what needs to happen before it reaches a prescription pad.

This article covers the dual GLP-1/GIP receptor agonist mechanism that defines VK2735's pharmacology, the injectable VENTURE and oral VENTURE-Oral trial programs, where VK2735 sits in the broader incretin drug pipeline, and which biomarkers are relevant for anyone evaluating metabolic health in this context.

Key Takeaways

• Regulatory Status: As of April 2026, VK2735 is not FDA-approved for any indication. It is an investigational new drug in active Phase 3 development. Not available by prescription or through compounding.
• Research Stage: Phase 2 injectable VENTURE trial published; Phase 3 VANQUISH-1 (obesity) and VANQUISH-2 (type 2 diabetes) enrollment completed; Phase 2 oral VENTURE-Oral underway; Phase 3 oral trial planned for Q3 2026.
• Availability: Not available for human use outside of clinical trial enrollment. Superpower does not offer this compound. For enrollment information, see ClinicalTrials.gov NCT06068946.
• Prescribing information: No FDA label exists. Reference: VENTURE trial registration (NCT06068946).
• How it works: Simultaneously activates GLP-1 receptors (appetite suppression, slowed gastric emptying) and GIP receptors (incretin synergy, potential enhanced tolerability).
• What the research shows: In the VENTURE Phase 2 trial, once-weekly subcutaneous VK2735 produced mean weight reductions of 9.1% to 14.7% versus 1.7% with placebo at 13 weeks. Phase 3 data are pending.

Where VK2735 Comes From and How It Works

Origin and development

VK2735 is a synthetic peptide developed by Viking Therapeutics, a San Diego-based biopharmaceutical company focused on metabolic and endocrine disorders. Viking initiated the compound's clinical development as a subcutaneous injectable, then expanded to an oral tablet formulation. This two-formulation strategy mirrors the broader industry interest in transitioning incretin therapies from injection to oral delivery. The subcutaneous program progressed through Phase 2 and entered Phase 3 development in 2025. The oral program, developed separately, entered Phase 2 in early 2025. Both programs target obesity; the Phase 3 VANQUISH-2 trial also evaluates the compound in adults with obesity and type 2 diabetes.

The GLP-1 receptor component

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Its receptor, GLP-1R, is expressed in the pancreas, gastrointestinal tract, and brain. Activation of GLP-1R produces several metabolic effects: glucose-dependent stimulation of insulin secretion, suppression of glucagon release, slowing of gastric emptying, and hypothalamic signaling that reduces appetite and increases satiety. A comprehensive 2019 review by Müller and colleagues in Molecular Metabolism, covering the full spectrum of GLP-1 biology from signaling through therapeutic applications, established that GLP-1's physiological effects extend well beyond insulin secretion, including cardioprotective, neuroprotective, and anti-inflammatory actions. In the context of VK2735, the GLP-1R component is the mechanism underlying the bulk of the appetite and satiety effects observed in clinical trials.

The GIP receptor component and the agonism-versus-antagonism debate

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, secreted by intestinal K-cells. The role of GIPR agonism in obesity pharmacology has been the subject of genuine scientific debate: two competing strategies have emerged from different drug development programs. Tirzepatide (FDA-approved, Eli Lilly) and VK2735 (investigational, Viking Therapeutics) both use GIPR agonism, activating the receptor to enhance insulin secretion and potentially modulate the tolerability of GLP-1R agonism by attenuating nausea signaling. A 2018 characterization of tirzepatide by Coskun and colleagues in Molecular Metabolism established the mechanistic rationale for the dual GIP/GLP-1 agonist approach, demonstrating meaningful metabolic advantages over GLP-1R agonism alone in preclinical models and early human studies. The broader scientific argument for dual incretin co-agonism traces back to a 2013 paper in Science Translational Medicine by Finan and colleagues, which established balanced GIP/GLP-1 co-agonism as a superior metabolic strategy in rodents, monkeys, and humans and defined the foundational "unimolecular dual incretins" concept that the entire class VK2735 belongs to was built on. A 2023 review in Cell Metabolism by Campbell, Müller, Finan and colleagues synthesized the chemistry, physiology, and clinical applications of GIPR/GLP-1R dual agonist therapies, framing the ongoing scientific debate over whether GIPR agonism or antagonism is the correct strategy for dual incretin design and explaining why both hypotheses remain clinically open. By contrast, MariTide (maridebart cafraglutide, Amgen) takes the opposing approach: GLP-1R agonism combined with GIPR antagonism, blocking the receptor rather than activating it. A 2025 Phase 2 obesity trial by Jastreboff and colleagues published in the New England Journal of Medicine (N = 592; 465 adults with obesity and 127 with obesity plus type 2 diabetes) randomized participants to MariTide 140 mg, 280 mg, or 420 mg every 4 weeks, 420 mg every 8 weeks, or placebo for 52 weeks. In the obesity cohort, mean weight reduction ranged from -12.3% (95% CI, -15.0 to -9.7) to -16.2% versus -2.5% (95% CI, -4.2 to -0.7) with placebo; in the obesity-plus-diabetes cohort, reductions ranged from -8.4% (95% CI, -11.0 to -5.7) to -12.3% versus -1.7% with placebo. Gastrointestinal adverse events were common but attenuated with dose escalation. Whether agonism or antagonism of the GIP receptor produces superior outcomes in head-to-head comparison remains unresolved; VK2735 and tirzepatide represent the agonism hypothesis, while MariTide represents the antagonism hypothesis. No published clinical trial has directly compared these two strategies.

Why dual agonism was hypothesized to outperform single agonism

The scientific premise underlying both VK2735 and tirzepatide is that activating two incretin pathways simultaneously produces metabolic effects beyond what either pathway achieves alone. Nogueiras, Nauck, and Tschöp published a 2023 review in Nature Metabolism tracing the development of gut hormone co-agonists from preclinical origins through the first clinical approvals, noting that the dual GLP-1/GIP approach produced what the authors described as "unprecedented weight loss of up to 22.5%" in non-diabetic adults with obesity in SURMOUNT-1. The question for VK2735 is whether its specific molecular design produces a comparable or differentiated profile relative to tirzepatide in a head-to-head setting, a comparison that, as of April 2026, has not been completed.

What the Human Evidence Shows

The VENTURE Phase 2 injectable trial

The primary published evidence base for VK2735 is the VENTURE trial, a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of once-weekly subcutaneous VK2735 in 176 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) plus at least one weight-related comorbidity, excluding adults with type 2 diabetes. Bays and colleagues published the full results in a 2026 Obesity paper. The primary endpoint was percentage change in body weight from baseline to 13 weeks.

Across weekly doses of 2.5 mg, 5 mg, 10 mg, and 15 mg, VK2735 produced mean weight reductions of 9.1% at 2.5 mg and 14.7% at 15 mg, compared to 1.7% with placebo (all active-dose comparisons statistically significant versus placebo). The ≥5% weight-reduction responder rate was 93% (130/140) in the pooled active groups versus 12% (4/34) on placebo. Gastrointestinal adverse events — predominantly nausea, vomiting, diarrhea, and constipation — were the most commonly reported side effects, consistent with the GLP-1R agonist class profile, and decreased in frequency after dose titration reached steady state. The 13-week duration limits inference about longer-term durability and safety, which the 78-week VANQUISH program is designed to address.

Two context points are essential for interpreting these results. First, the 13-week time horizon is short by the standards of published obesity trials. The SURMOUNT-1 trial of tirzepatide extended to 72 weeks, and STEP 1 for semaglutide ran to 68 weeks. Whether VK2735's 14.7% weight reduction at 13 weeks translates to outcomes comparable to those established over longer durations for approved agents is not yet known; that answer will come from the Phase 3 VANQUISH program. Second, the VENTURE trial excluded adults with type 2 diabetes, meaning the data do not address that population specifically. The Phase 3 VANQUISH-2 trial is addressing this gap.

The VENTURE-Oral Phase 2 trial

A separate development track for VK2735 involves an oral tablet formulation. Viking Therapeutics initiated the Phase 2 VENTURE-Oral trial (NCT06828055) in early 2025, targeting adults with obesity. Oral delivery of peptide-based GLP-1/GIP agonists represents a fundamental pharmaceutical challenge: peptides are degraded in the gastrointestinal tract, and achieving therapeutic plasma concentrations from oral dosing requires either a specialized absorption enhancer or a peptide engineered for exceptional stability against proteolysis. The mechanism by which oral semaglutide achieves clinically relevant absorption involves SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]), a co-formulation agent that enables transcellular gastric absorption by temporarily buffering the local environment near the tablet surface. This mechanism was characterized in detail by Buckley and colleagues in a 2018 study in Science Translational Medicine. The OASIS 1 trial, published in 2023 by Knop and colleagues in The Lancet, established that oral semaglutide at 50 mg once daily produced approximately 15% weight loss at 68 weeks, demonstrating that oral peptide delivery can achieve meaningful efficacy when bioavailability challenges are addressed. The pharmacokinetics underlying that efficacy are nontrivial: a 2019 single- and multiple-ascending-dose study by Granhall and colleagues in Clinical Pharmacokinetics characterized oral semaglutide exposure in healthy subjects and adults with type 2 diabetes, documenting the bioavailability variability (approximately 0.4 to 1 percent) and food and water-timing sensitivity that define oral peptide GLP-1 therapy. These technical realities are directly relevant to how any oral VK2735 program must handle dose titration and patient education. Whether VK2735's oral formulation achieves a comparable pharmacokinetic profile is what the Phase 2 VENTURE-Oral trial is designed to determine. As of April 2026, Phase 2 results from VENTURE-Oral have not been published. Viking has announced plans to advance the oral program into Phase 3 in Q3 2026, contingent on those results.

The oral GLP-1 field is not exclusively peptide-based. Orforglipron, a non-peptide oral GLP-1R agonist developed by Eli Lilly, was studied in a 272-participant Phase 2 trial by Wharton and colleagues in the New England Journal of Medicine (2023) in adults with obesity, randomizing participants to orforglipron 12, 24, 36, or 45 mg daily or placebo for 36 weeks. Mean weight change at week 36 ranged from -9.4% to -14.7% across active doses versus -2.3% with placebo, and 46-75% of orforglipron-treated participants achieved ≥10% weight loss compared to 9% on placebo. Orforglipron bypasses the peptide bioavailability challenge entirely by using a small-molecule scaffold that does not require SNAC or equivalent absorption enhancement. How VK2735 oral compares to non-peptide alternatives, in terms of bioavailability, tolerability, and efficacy, remains an open question.

Regulatory and Legal Status

FDA classification and current status

As of April 2026, VK2735 is an investigational new drug (IND) under active development by Viking Therapeutics. It has not received FDA approval for any indication, has not been submitted for NDA review, and is not available by prescription or through licensed compounding pharmacies. VK2735 is not a Category 2 bulk drug substance (the designation that restricts previously compounded peptides); it was never available through compounding pharmacies and does not fall under the FDA's bulk drug substance evaluation framework. The regulatory restriction on VK2735 is simply that it has not completed the approval process, not that it was previously accessible and has been reclassified.

The Phase 3 VANQUISH program

Viking Therapeutics initiated the Phase 3 VANQUISH program in 2025. VANQUISH-1 is a randomized, double-blind, placebo-controlled, multicenter trial evaluating once-weekly subcutaneous VK2735 for 78 weeks in approximately 4,650 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) plus at least one weight-related comorbidity. Enrollment in VANQUISH-1 was completed in November 2025. VANQUISH-2 evaluates VK2735 in adults with obesity and type 2 diabetes; enrollment was completed in Q1 2026. With 78-week treatment periods and the time required for data analysis and NDA preparation, FDA approval for the subcutaneous formulation is not anticipated before 2028 at the earliest.

What would need to happen for VK2735 to become available

Three events are required before VK2735 can be prescribed in the United States. First, the Phase 3 VANQUISH-1 trial must demonstrate statistically significant and clinically meaningful superiority over placebo on the primary endpoint (percentage weight change at 78 weeks) with an acceptable safety profile. Second, Viking must submit an NDA to the FDA containing the full Phase 3 dataset, including VANQUISH-2 data for the diabetic obesity indication. Third, the FDA must complete its review and grant approval, a process that takes approximately 10 to 12 months under standard review and 6 months under priority review designation. No FDA guidance on priority review designation for VK2735 has been issued as of April 2026. Whether any approved formulation would be commercially manufactured by Viking or made available through a partnership arrangement is not yet determined.

What this means practically

VK2735 is not prescribable and not available through any legal pathway in the United States as of April 2026. Products sold online as "VK2735" are unregulated and carry the same risks inherent to any injectable compound purchased outside a regulated pharmaceutical supply chain: unknown purity, uncertain concentration, absent sterility testing, and no manufacturing oversight. Independent compound testing programs have consistently identified contamination and dosing errors in unregulated injectable peptides. There is no compounded form of VK2735 that is legal to prescribe or dispense in the US, because VK2735 has no legal compounding pathway. The compound is neither FDA-approved nor a permitted bulk drug substance for compounding under Section 503A.

VK2735 in Context: The Incretin Pipeline

VK2735 enters clinical development into a class that already includes approved dual agonists, approved GLP-1 monotherapy, and a growing number of investigational triple and combination agents. Understanding where VK2735 fits requires a precise reading of what the existing data show for each comparator, and an honest acknowledgment of what cross-trial comparisons cannot reliably establish.

Tirzepatide: the approved dual GIP/GLP-1 benchmark

Tirzepatide (FDA-approved for T2D in 2022 and obesity in 2023; branded as Mounjaro and Zepbound) is the closest mechanistic comparator to VK2735 in clinical use. Both are dual GIP/GLP-1 receptor agonists. Tirzepatide's efficacy in obesity is established at a higher level of evidence: the SURMOUNT-1 trial by Jastreboff and colleagues, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity (without diabetes) 1:1:1:1 to once-weekly subcutaneous tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. Mean weight reduction was -15.0% (95% CI, -15.9 to -14.2) with 5 mg, -19.5% (95% CI, -20.4 to -18.5) with 10 mg, and -20.9% (95% CI, -21.8 to -19.9) with 15 mg, versus -3.1% (95% CI, -4.3 to -1.9) with placebo (all p < 0.001). At the 15 mg dose, 57% (95% CI, 53-61) of participants achieved ≥20% weight reduction versus 3% (95% CI, 1-5) with placebo. Adverse-event-driven discontinuation occurred in 4.3%, 7.1%, and 6.2% of the 5, 10, and 15 mg arms respectively versus 2.6% with placebo, predominantly for gastrointestinal events during titration. In type 2 diabetes, the SURPASS-2 trial by Frías and colleagues in the New England Journal of Medicine (2021) directly compared tirzepatide to semaglutide 1 mg in 1,879 adults over 40 weeks, finding that tirzepatide produced significantly greater reductions in HbA1c and body weight across all three doses tested. SURMOUNT-2, published in 2023 by Garvey and colleagues in The Lancet, extended the evidence base into 938 adults with obesity (BMI ≥27) and type 2 diabetes (HbA1c 7-10%), randomizing to tirzepatide 10 mg, 15 mg, or placebo for 72 weeks; mean weight change was -12.8% with 10 mg and -14.7% with 15 mg versus -3.2% with placebo (all p < 0.0001). SURMOUNT-3, published in 2023 by Wadden and colleagues in Nature Medicine, enrolled 579 adults who first underwent a 12-week intensive lifestyle lead-in and were then randomized 1:1 to tirzepatide or placebo for 72 additional weeks; from the post-lead-in baseline, the tirzepatide arm experienced an additional -18.4% body weight change versus +2.5% with placebo (treatment difference -20.8 percentage points, p < 0.001), with 87.5% versus 16.5% achieving an additional ≥5% reduction. This establishes that pharmacotherapy layers on top of behavioral intervention rather than substituting for it. This result provides the key clinical argument that GIP receptor co-activation adds incremental metabolic benefit beyond GLP-1R agonism alone. VK2735 and tirzepatide share this mechanistic hypothesis, but VK2735's evidence base is limited to a 13-week Phase 2 trial. The SURMOUNT-1 72-week data and VK2735's 13-week data are not comparable in any rigorous sense. Any meaningful head-to-head comparison awaits Phase 3 VANQUISH results.

Semaglutide: the GLP-1 monotherapy benchmark

Semaglutide (FDA-approved for T2D and obesity; branded as Ozempic, Wegovy, and Rybelsus) activates only the GLP-1R. In STEP 1, Wilding and colleagues reported in the New England Journal of Medicine (2021) that once-weekly subcutaneous semaglutide 2.4 mg produced mean weight reduction of 14.9% at 68 weeks in 1,961 adults with obesity, versus 2.4% with placebo. This establishes the minimum threshold VK2735 would need to exceed at 78 weeks to make a compelling case for GIPR co-activation in the context of obesity. Semaglutide's cardiovascular outcome data are more extensive than any newer agent's. The SELECT trial, published in 2023 by Lincoff and colleagues in the New England Journal of Medicine (N = 17,604 adults ≥45 years with preexisting cardiovascular disease and BMI ≥27 but without diabetes), randomized participants to once-weekly semaglutide 2.4 mg or placebo over a mean follow-up of 39.8 ± 9.4 months. The primary composite MACE endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke) occurred in 6.5% of semaglutide-treated participants versus 8.0% with placebo (hazard ratio 0.80, 95% CI 0.72-0.90, p < 0.001). Adverse-event-driven discontinuation was 16.6% versus 8.2%. Replicating this cardiovascular benefit for VK2735 would require a dedicated outcome trial of similar size and duration. No cardiovascular outcome trial for VK2735 has been initiated.

CagriSema: a non-GIP combination strategy

Not every emerging obesity therapy depends on the GIP receptor. CagriSema, a coadministration of cagrilintide (a long-acting amylin analog) with semaglutide, tests whether combining GLP-1R agonism with amylin agonism can rival dual GLP-1/GIP strategies. The REDEFINE-1 trial, published in 2025 by Garvey and colleagues in the New England Journal of Medicine (N = 3,417 adults with obesity or BMI ≥27 plus an obesity-related complication, without diabetes), randomized participants to once-weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg or placebo for 68 weeks and reported mean weight reduction of -20.4% with CagriSema versus -3.0% with placebo (estimated treatment difference -17.3 percentage points, 95% CI -18.1 to -16.6, p < 0.001). REDEFINE-2, published the same year by Davies and colleagues in the New England Journal of Medicine, extended the assessment to adults with BMI ≥27, HbA1c 7-10%, and type 2 diabetes, randomizing 3:1 to CagriSema or placebo for 68 weeks; mean weight change was -13.7% with CagriSema versus -3.4% with placebo (estimated difference -10.4 percentage points, p < 0.001), with 74% of the CagriSema arm reaching HbA1c ≤6.5% versus 15.9% on placebo. Together these trials provide a contemporary comparator to VK2735's dual GIP/GLP-1 approach, using an entirely different receptor combination. Cross-trial comparisons remain unreliable, but the existence of multiple viable combination strategies underscores that "dual GIP/GLP-1 agonism" is one hypothesis among several, not the only route to clinically meaningful weight loss in this pipeline.

Retatrutide: the triple agonist benchmark

Retatrutide (Eli Lilly) adds glucagon receptor agonism to the GLP-1/GIP combination, creating a triple agonist. The Phase 2 trial by Jastreboff and colleagues in the New England Journal of Medicine (2023) randomized 338 adults with obesity to placebo or retatrutide at 1, 4, 8, or 12 mg weekly for 48 weeks. Least-squares mean body-weight change at 48 weeks was -24.2% at the 12 mg dose versus -2.1% with placebo — the largest reduction in any published obesity pharmacotherapy trial to date — though the single-trial, 48-week Phase 2 design limits direct comparison to the 72-week Phase 3 benchmarks established for tirzepatide and semaglutide. Whether this reflects the additional glucagon receptor component, differences in trial duration, or population-level variation compared to VK2735's Phase 2 data cannot be determined from cross-trial comparison alone. Cross-trial comparisons are unreliable due to differences in study design, patient populations, and endpoints. VK2735 and retatrutide are in the same mechanistic neighborhood but differ in their second target (GIP receptor for VK2735 versus glucagon receptor for retatrutide). This comparison is for scientific context only; these compounds have different regulatory statuses and evidence bases.

The broader pipeline context

Two recent pipeline reviews provide useful framing for where VK2735 sits within the full obesity pharmacotherapy landscape. A 2025 review in International Journal of Obesity by Melson and colleagues surveyed the obesity pharmacotherapy pipeline across tirzepatide, CagriSema, retatrutide, and emerging candidates, placing comparator class efficacy numbers in one synthesis. A 2025 systematic review in Pharmacological Reviews by Kokkorakis and colleagues analyzed 36 emerging antiobesity drugs in Phase 2 and Phase 3 development, providing the most comprehensive peer-reviewed catalog currently available. Notably, VK2735 was not included in that review, which is an honest reminder that peer-reviewed literature lags behind press releases and investor communications for compounds at this stage of development.

Weight regain: a class-level consideration

One established pattern across the GLP-1 agonist and dual agonist class is weight regain after discontinuation. The SURMOUNT-4 trial, published by Aronne and colleagues in JAMA (2024), enrolled 783 adults with obesity in a 36-week open-label tirzepatide lead-in (mean weight reduction -20.9%), then randomized 670 participants 1:1 to continued tirzepatide or placebo for an additional 52 weeks. Mean body-weight change from week 36 to week 88 was -5.5% with continued tirzepatide versus +14.0% with placebo (treatment difference -19.4 percentage points, p < 0.001), and 89.5% of the continued-tirzepatide arm maintained at least 80% of their lead-in weight loss versus 16.6% on placebo (p < 0.001). This establishes that ongoing treatment is necessary for weight maintenance in this drug class. There is no specific data on weight regain after VK2735 discontinuation, but the mechanism is the same: receptor agonism is not a permanent physiological change, and cessation of treatment likely reverses the behavioral and metabolic effects that produced the weight loss. Providers evaluating any GLP-1/GIP dual agonist, including VK2735 if it receives approval, should understand this as a chronic-therapy implication.

Lean mass: a shared limitation of the class

A 2024 review by Stefanakis and colleagues in Metabolism reported that more than 25% of total weight lost on GLP-1 receptor agonist therapy is fat-free mass, including skeletal muscle. The authors noted that this muscle loss can impair metabolic health and increase the risk of sarcopenic obesity, and that the issue is often overlooked in clinical discussions of weight loss efficacy. Whether VK2735 produces a lean mass loss profile that differs from other GLP-1/GIP dual agonists has not been established in published data. This is a class-level caveat applicable to VK2735 as well as to tirzepatide and semaglutide.

Safety: What Is and Is Not Known

Clinical safety from VENTURE

The published safety profile from VENTURE is consistent with the tolerability pattern established across the GLP-1 agonist class. Gastrointestinal adverse events (primarily nausea, vomiting, diarrhea, and constipation) were the most commonly reported side effects and were typically mild to moderate in severity. These events occurred most frequently during dose titration and decreased in reported frequency once titration reached steady state, a pattern observed with tirzepatide and semaglutide as well. A 2022 analysis by Wharton and colleagues in Diabetes, Obesity and Metabolism examined the gastrointestinal adverse-event profile of once-weekly semaglutide 2.4 mg and its relationship to weight-loss outcomes, providing an honest reference framing for what patients on any GLP-1-based agent, including VK2735, can expect in terms of nausea and vomiting frequency. Discontinuation rates due to adverse events in VENTURE were not prominently reported in the published Phase 2 data. Long-term safety beyond 13 weeks has not been characterized in any published VK2735 study; that data will emerge from the 78-week VANQUISH program.

Common side effects reported in VENTURE:

• Nausea (most common; most frequent during dose titration)
• Vomiting
• Diarrhea
• Constipation

Class-level safety considerations not yet characterized for VK2735 specifically:

• Cardiovascular outcomes (no CVOT initiated as of April 2026)
• Thyroid C-cell effects (applies to GLP-1R agonist class based on rodent data; no human thyroid signal established for this class but it is included in FDA labeling for approved GLP-1R agonists)
• Pancreatitis risk (class-level consideration; not characterized specifically for VK2735)
• Lean mass and bone density effects at 78 weeks (Phase 3 will generate this data)

Risks from unregulated sources

VK2735 is available from online vendors selling unregulated injectable peptides. These products carry no manufacturing oversight, no independent purity testing, no sterility verification, and no guarantee that the compound is what is claimed. The specific risks include microbial contamination, heavy metal contamination, misidentified compounds, and dosing concentrations that differ substantially from what is labeled. These risks are not theoretical. Independent testing programs have documented contamination and mislabeling across the unregulated injectable peptide market broadly. Because VK2735 has not completed clinical development, there is also no established safe dose range that could serve as a reference point for unregulated use.

Who Should Not Use VK2735

VK2735 should not be used outside clinical trial enrollment. For those evaluating the risk profile based on the compound's mechanisms, the following groups face elevated risk and would require particular clinical scrutiny if VK2735 eventually receives FDA approval:

• Adults with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2): a risk category consistent with all GLP-1R agonists based on the thyroid C-cell signal established in rodent studies and reflected in FDA class labeling.
• Adults with a history of pancreatitis: a risk consideration consistent with the GLP-1 agonist class; causal relationship in humans has not been established but the association is reflected in prescribing guidance for approved agents.
• Adults with severe gastroparesis or gastrointestinal motility disorders: GLP-1R agonism slows gastric emptying, which may worsen these conditions.
• Pregnant or breastfeeding adults: safety during pregnancy and lactation has not been studied; GLP-1/GIP dual agonist use during pregnancy is not appropriate without established safety data.
• Adults with severe renal or hepatic impairment: pharmacokinetics in these populations have not been characterized in published VK2735 data.

This list is not exhaustive and is derived from class-level mechanistic considerations for GLP-1R agonists, not from VK2735-specific clinical data. A licensed provider will conduct a full clinical evaluation before determining eligibility if VK2735 receives FDA approval.

Which Biomarkers Are Relevant if You Are Evaluating Metabolic Health?

Whether or not VK2735 eventually becomes available, the biomarkers that inform weight-related metabolic evaluation are the same ones that matter now. Understanding your metabolic baseline is a useful clinical step regardless of which compound is accessible at any given point in the pipeline.

• Hemoglobin A1c (HbA1c): Reflects average blood glucose over the preceding two to three months. It is a standard measure of glycemic control and serves as both an eligibility and efficacy endpoint in obesity and diabetes trials. The VENTURE trial specifically excluded adults with T2D; HbA1c is the primary criterion for that distinction. You can review what HbA1c measures and how it is interpreted in the context of metabolic health.
• Fasting insulin: A sensitive marker of insulin resistance that is often not ordered on standard metabolic panels. Elevated fasting insulin in the setting of normal or borderline-high fasting glucose indicates compensated insulin resistance, the metabolic condition that GLP-1/GIP dual agonist therapy addresses. Relevant biomarkers for blood sugar stability and insulin sensitivity include fasting insulin alongside fasting glucose and HbA1c.
• Fasting glucose: The most basic glycemic marker. In the context of GLP-1/GIP dual agonist evaluation, fasting glucose establishes baseline and distinguishes obesity without impaired fasting glucose from prediabetes and T2D, distinctions that determine which clinical trial population a given person maps to.
• Body weight and BMI: Trial inclusion criteria for VENTURE and VANQUISH are BMI-based. Understanding your BMI in the context of the current evidence base clarifies which approved or investigational therapies you might qualify for.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides): GLP-1/GIP dual agonist therapy has been associated with improvements in lipid parameters in clinical trials, particularly triglyceride reduction. Baseline lipid values establish the pre-treatment context against which any future changes can be measured. Biomarkers for metabolic health and weight management include the lipid panel as part of a comprehensive baseline assessment.
• Cardiovascular risk markers (ApoB, hsCRP): The cardiovascular benefit of GLP-1R agonism is one of the most significant findings in the class, but VK2735 has no cardiovascular outcome data yet. Establishing your cardiovascular risk profile at baseline, including ApoB and high-sensitivity CRP, provides context for understanding what metabolic pharmacotherapy might eventually offer in your specific case. You can explore cardiovascular health biomarkers worth testing.
• Lean mass markers (muscle mass via DEXA or impedance; creatinine as a proxy): Given the published evidence that more than 25% of weight lost on GLP-1 therapy is fat-free mass, tracking lean mass before and during any obesity pharmacotherapy is clinically meaningful. An understanding of your body composition baseline makes the question of lean mass preservation interpretable against objective measurements. Body composition biomarkers include the relevant measures for this assessment.
• Thyroid function (TSH, free T4): The GLP-1R agonist class carries a class-level label warning regarding thyroid C-cell effects based on rodent data. While no human thyroid cancer signal has been established in the approved GLP-1R agonists, thyroid function baseline is a standard pre-treatment assessment in clinical practice for any GLP-1-adjacent therapy.

The Bottom Line

VK2735 is one of the better-positioned investigational obesity compounds in the current pipeline, with a published Phase 2 trial, a mechanistic rationale grounded in the same dual GIP/GLP-1 agonism that underlies an already-approved drug class, and a Phase 3 program that has completed enrollment. The gap between those facts and clinical availability is still substantial: 78 weeks of VANQUISH-1 data, NDA preparation, FDA review, and commercial manufacturing arrangements all stand between the current evidence base and a prescription pad. For the oral formulation, the timeline extends further. For anyone evaluating where VK2735 fits in their own clinical picture, the most useful step is not to track Viking's investor releases but to understand the metabolic biomarkers that will determine eligibility, response, and risk in any obesity pharmacotherapy, whether that is VK2735 after approval, a currently available GLP-1/GIP agent, or a different intervention entirely.

That orientation, testing to understand biology before making clinical decisions, is central to Superpower's approach to preventive health: the belief that objective biomarker data should inform every clinical decision, whether the compound in question is available today or still working through a 78-week Phase 3 trial.

IMPORTANT SAFETY INFORMATION

VK2735 is NOT FDA-approved for any indication. It is an investigational new drug in Phase 3 clinical development under Viking Therapeutics' active IND (the VANQUISH program). VK2735 is not a Category 2 bulk drug substance under FDA Section 503A and has never been reviewed for compounding eligibility because it was never available through compounding pharmacies; it is not eligible for compounding under 503A or 503B pathways. VK2735 is not available by prescription, through licensed compounding pharmacies, or by any legal pathway in the United States as of April 2026. Superpower is a technology platform; Superpower does not prescribe, sell, compound, or dispense investigational medications.

No boxed warning exists for VK2735 as no approved labeling has been issued. Class-level GLP-1 receptor agonist labeling for approved agents includes a warning regarding thyroid C-cell tumors based on rodent studies; a causal relationship in humans has not been established. Whether this class-level signal applies to VK2735 will be addressed in Phase 3 safety data and, if relevant, in FDA-approved labeling upon approval.

Contraindications (based on class-level mechanisms; not established from VK2735-specific data): personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2); known hypersensitivity to VK2735 or its excipients; pregnancy or breastfeeding (safety not established).

Warnings (class-level, not VK2735-specific): gastrointestinal adverse events including nausea, vomiting, diarrhea, and constipation; pancreatitis risk (class consideration; causal relationship in humans not established); gastroparesis exacerbation; lean mass loss with prolonged weight reduction therapy.

Common side effects reported in VENTURE Phase 2 trial: nausea, vomiting, diarrhea, constipation. Most were mild to moderate and decreased after dose titration. Long-term safety data have not been published.

Not a complete list of risks. Full safety information will be available in FDA-approved prescribing information upon approval, if granted. Until that time, VK2735 should not be used outside of authorized clinical trial enrollment.

Additional Questions

Will VK2735 become available through compounding pharmacies?

This is unlikely regardless of eventual FDA approval. Compounding pharmacies dispense compounded versions of FDA-approved drug substances when specific conditions are met. VK2735 is Viking Therapeutics' proprietary investigational compound; even after potential approval, access would be through commercially manufactured branded product, not compounding. The current FDA enforcement posture on compounded GLP-1 agents adds additional uncertainty to any compounding pathway for newer drugs in this class.

What are the side effects of VK2735?

In the published VENTURE Phase 2 trial, gastrointestinal adverse events were the most common side effects, including nausea, vomiting, diarrhea, and constipation. These were predominantly mild to moderate and decreased in frequency after dose titration reached steady state, consistent with the tolerability pattern of the GLP-1 agonist class broadly. Long-term safety data beyond 13 weeks have not been published; the 78-week VANQUISH program will generate the comprehensive safety profile required for NDA submission.

What is the VANQUISH trial?

VANQUISH is Viking Therapeutics' Phase 3 clinical trial program for subcutaneous VK2735. VANQUISH-1 evaluates approximately 4,650 adults with obesity or overweight over 78 weeks; enrollment was completed in November 2025. VANQUISH-2 evaluates VK2735 in adults with obesity and type 2 diabetes; enrollment was completed in Q1 2026. These trials will generate the efficacy and safety data required for an NDA submission to the FDA.